This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Lexicon Pharmaceuticals, Inc. (LXRX)
Q2 2012 Earnings Call
July 31, 2012, 11:00 a.m. ET
Alex Abuin – VP Communications and Alliance Management
Dr. Arthur Sands – President and CEO
Brian Zambrowicz, EVP, Chief Scientific Officer
Jeff Wade – EVP, Corporate Development and Chief Financial Officer
Matt Lowe – JPMorgan
Liana Moussatos – Wedbush Securities
Alan Carr – Needham & Company
David Friedman – Morgan Stanley
Nicholas Bishop – Cowen and Company
Stephen Willey – Stifel Nicolaus
Thank you for holding. Welcome to the Lexicon Pharmaceuticals' Second Quarter 2012 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Lexicon’s request.
At this time, I would like to introduce your host for today’s call, Alex Abuin, Vice President Communications and Alliance Management. Please go ahead Doctor Abuin.
Good morning and welcome to the Lexicon Pharmaceuticals' second quarter 2012 conference call. I am Alex Abuin, and with me today are Dr. Arthur Sands, Lexicon’s President and Chief Executive Officer; Dr. Brian Zambrowicz, Lexicon’s Executive Vice President and Chief Scientific Officer; Dr. Jeff Wade, Lexicon’s Senior Vice President of Clinical Development and Chief Medical Officer.
We expect that you have seen a copy of our earnings press release that was distributed this morning. During this call, we will review the information provided in the release, provide an update on our clinical programs, and then use the remainder of our time to answer your questions.